Affordable Access

deepdyve-link
Publisher Website

Clinical value of Flash glucose monitoring in patients with type 1 diabetes treated with continuous subcutaneous insulin infusion.

Authors
  • Moreno-Fernandez, Jesus1
  • Pazos-Couselo, Marcos2
  • González-Rodriguez, Maria2
  • Rozas, Pedro3
  • Delgado, Manuel3
  • Aguirre, Miguel3
  • Garcia-Lopez, Jose Manuel2
  • 1 Endocrinology and Nutrition Service, Ciudad Real General University Hospital, Ciudad Real, Spain. Electronic address: [email protected] , (Spain)
  • 2 Endocrinology and Nutrition Service, Hospital Complex Santiago de Compostela, Santiago de Compostela, Spain. , (Spain)
  • 3 Endocrinology and Nutrition Service, Ciudad Real General University Hospital, Ciudad Real, Spain. , (Spain)
Type
Published Article
Journal
Endocrinologia, diabetes y nutricion
Publication Date
Dec 01, 2018
Volume
65
Issue
10
Pages
556–563
Identifiers
DOI: 10.1016/j.endinu.2018.04.003
PMID: 29907546
Source
Medline
Keywords
Language
Spanish
License
Unknown

Abstract

To analyze the clinical impact of the Flash glucose monitoring system in patients with type 1 diabetes mellitus (T1DM) treated with continuous subcutaneous insulin infusion (CSII). A 24-week retrospective cohort study in CSII-treated T1DM patients exposed (1:1) to the Flash glucose monitoring system vs. self-monitoring of capillary blood glucose (SMBG). The primary outcome was the difference in hemoglobin A1c (HbA1c) levels between both groups at the end of the study. Thirty-six patients with a mean age of 38.2 years (range 22-55) and a mean T1DM duration of 20.9±7.8 years, treated with CSII for 7.1±5.4 years, were enrolled into the study. At the end of the study, mean HbA1c levels improved in patients in the Flash group (7.1±0.7 vs. 7.8±1.0, p=0.04). Only the Flash group showed a significant decrease in HbA1c levels of -0.4% (95% CI, -0.6, -0.2; p=0.004) during follow-up. Flash patients captured 93.9% of data through 17.8±9.9 scans daily. In fact, the Flash cohort showed a three-fold increase in daily self-monitoring of glucose, while daily frequency of SMBG decreased during the study (-1.8 tests/24h (95% CI -3, -0.7; p=0.01). No safety issues related to Flash use were recorded. The Flash glucose monitoring system is a novel approach to improve blood glucose control in CSII-treated T1DM patients. Randomized controlled trials are needed to assess the effectiveness of this system in CSII-treated T1DM patients. Copyright © 2018 SEEN y SED. Publicado por Elsevier España, S.L.U. All rights reserved.

Report this publication

Statistics

Seen <100 times